The makers of pharmaceuticals including OxyContin and Percocet are moving a second time to dismiss a groundbreaking suit filed by the city of Chicago that links the use of the opioids to a growing population of drug addicts.
The city, which pays for the drugs as part of its employee health plans, claims that five opioid drug makers, including Purdue Pharma L.P., maker of OxyContin and Dilaudid, and Endo Pharmaceuticals Inc., maker of Opana and Percocet, have promoted their products as safe for chronic pain management despite generally accepted knowledge of their addictive nature. The drugs are approved for temporary pain relief associated with surgeries or cancer. The marketing campaign, the suit alleges, has led to increasing drug overdoses in Chicago’s hospitals and has fueled a resurgence of heroin use.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
